Kromek Swings to Profit on Siemens-Backed Imaging Surge and Strong CBRN Demand

Kromek Group plc ( (GB:KMK) ) just unveiled an announcement.

Kromek Group reported a sharp turnaround in performance for the six months to 31 October 2025, with revenue surging to £15.0m from £3.7m a year earlier and a move from a pre-tax loss of £5.7m to a £3.1m profit, driven by strong growth in both its Advanced Imaging and CBRN detection divisions. Advanced Imaging sales jumped to £10.8m, heavily boosted by milestone deliveries under last year’s landmark Siemens Healthineers enablement agreement, while underlying imaging revenue still rose 41%, and CBRN revenue more than doubled to £4.3m on the back of key government wins, including a £1.7m order under the UK Radiological Nuclear Detection Framework and a development contract with the UK Ministry of Defence. Gross margins improved to 71.7% and adjusted EBITDA swung to a £6.0m profit, aided by higher-margin licensing income and ongoing automation and capacity expansion in CZT manufacturing, while an expanded £6.0m revolving credit facility and additional asset finance were secured to support growth. Management highlighted strengthening demand for CZT-based photon-counting CT and nuclear security solutions, renewed engagement with major OEM customers such as Spectrum Dynamics and Analogic, extensive patent activity, and a healthy order book, underpinning confidence that the group will deliver full-year results in line with market expectations and reinforcing its positioning as a key independent supplier in a growing, high-barrier imaging and security market.

The most recent analyst rating on (GB:KMK) stock is a Buy with a £14.50 price target. To see the full list of analyst forecasts on Kromek Group plc stock, see the GB:KMK Stock Forecast page.

Spark’s Take on GB:KMK Stock

According to Spark, TipRanks’ AI Analyst, GB:KMK is a Outperform.

The score is driven primarily by improved financial performance (strong revenue growth, expanding margins, and low leverage), tempered by mixed free cash flow trends. Technicals are supportive due to a strong uptrend and positive MACD, but overbought RSI/Stoch readings add pullback risk. Valuation is moderate on a 20.508 P/E with no dividend yield.

To see Spark’s full report on GB:KMK stock, click here.

More about Kromek Group plc

Kromek Group plc is a UK-headquartered developer of radiation detection and bio-detection technology serving advanced imaging and CBRN (chemical, biological, radiological and nuclear) detection markets. Listed on AIM in London, the company supplies cadmium zinc telluride (CZT)-based detector components for medical, security and industrial imaging, including CT and SPECT scanners, and provides compact nuclear radiation detectors and emerging bio-security systems for global homeland defence and critical infrastructure protection. It operates manufacturing facilities in the UK and US and positions its technology to enable higher-resolution imaging, better disease detection and enhanced protection against radiological and biological threats.

Average Trading Volume: 2,422,159

Technical Sentiment Signal: Buy

Current Market Cap: £74.52M

See more insights into KMK stock on TipRanks’ Stock Analysis page.